11 results on '"Yang, Jiali"'
Search Results
2. High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma.
- Author
-
Li, Ke, Yang, Jiali, Chen, Jiafei, Shi, Yanshu, Zhang, Zhuoli, and Chen, Wei
- Subjects
c-MYC ,high mobility group AT-hook 2 ,immunohistochemistry ,pancreatic ductal adenocarcinoma ,Rare Diseases ,Digestive Diseases ,Cancer ,Pancreatic Cancer ,Aetiology ,2.1 Biological and endogenous factors - Abstract
The present study investigated if c-MYC and high mobility group AT-hook 2 (HMGA2) expression was associated with prognosis of patients with pancreatic ductal adenocarcinoma (PDAC). A total of 102 patients undergoing surgery for PDAC were retrospectively reviewed. Immunohistochemistry was used to detect c-MYC and HMGA2 protein expression in PDAC and peritumoral tissue samples. Expression of c-MYC and HMGA2 was associated with clinicopathological characteristics and prognoses of patients with PDAC using multivariate analysis. HMGA2 and c-MYC protein expression was significantly higher in PDAC tissues compared with peritumoral tissue (P
- Published
- 2020
3. Contrast-enhanced CT radiomics for predicting lymph node metastasis in pancreatic ductal adenocarcinoma: a pilot study.
- Author
-
Li, Ke, Yao, Qiandong, Xiao, Jingjing, Li, Meng, Yang, Jiali, Hou, Wenjing, Du, Mingshan, Chen, Kang, Qu, Yuan, Li, Lian, Li, Jing, Wang, Xianqi, Luo, Haoran, Yang, Jia, Zhang, Zhuoli, and Chen, Wei
- Subjects
Humans ,Carcinoma ,Pancreatic Ductal ,Pancreatic Neoplasms ,Lymphatic Metastasis ,Tomography ,X-Ray Computed ,Pilot Projects ,Decision Support Techniques ,Models ,Theoretical ,Aged ,Middle Aged ,Female ,Male ,CT ,Lymph node metastasis ,Pancreatic ductal adenocarcinoma ,Radiomics ,Digestive Diseases ,Cancer ,Biomedical Imaging ,Pancreatic Cancer ,Rare Diseases ,Patient Safety ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Good Health and Well Being ,Oncology and Carcinogenesis ,Nuclear Medicine & Medical Imaging - Abstract
BACKGROUND:We developed a computational model integrating clinical data and imaging features extracted from contrast-enhanced computed tomography (CECT) images, to predict lymph node (LN) metastasis in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS:This retrospective study included 159 patients with PDAC (118 in the primary cohort and 41 in the validation cohort) who underwent preoperative contrast-enhanced computed tomography examination between 2012 and 2015. All patients underwent surgery and lymph node status was determined. A total of 2041 radiomics features were extracted from venous phase images in the primary cohort, and optimal features were extracted to construct a radiomics signature. A combined prediction model was built by incorporating the radiomics signature and clinical characteristics selected by using multivariable logistic regression. Clinical prediction models were generated and used to evaluate both cohorts. RESULTS:Fifteen features were selected for constructing the radiomics signature based on the primary cohort. The combined prediction model for identifying preoperative lymph node metastasis reached a better discrimination power than the clinical prediction model, with an area under the curve of 0.944 vs. 0.666 in the primary cohort, and 0.912 vs. 0.713 in the validation cohort. CONCLUSIONS:This pilot study demonstrated that a noninvasive radiomics signature extracted from contrast-enhanced computed tomography imaging can be conveniently used for preoperative prediction of lymph node metastasis in patients with PDAC.
- Published
- 2020
4. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer
- Author
-
Gu, Jianyou, Huang, Wenjie, Wang, Xianxing, Zhang, Junfeng, Tao, Tian, Zheng, Yao, Liu, Songsong, Yang, Jiali, Chen, Zhe-Sheng, Cai, Chao-Yun, Li, Jinsui, Wang, Huaizhi, and Fan, Yingfang
- Published
- 2022
- Full Text
- View/download PDF
5. The role of histone H1.2 in pancreatic cancer metastasis and chemoresistance.
- Author
-
Gu, Jianyou, Zhang, Junfeng, Xia, Renpei, Wang, Xianxing, Yang, Jiali, Xie, Fuming, Zhou, Qiang, Li, Jinghe, Zhang, Tao, Chen, Qing, Fan, Yingfang, Guo, Shixiang, and Wang, Huaizhi
- Abstract
Pancreatic cancer (PC) is a highly metastatic malignant tumor of the digestive system. Drug resistance frequently occurs during cancer treatment process. This study aimed to explore the link between chemoresistance and tumor metastasis in PC and its possible molecular and cellular mechanisms. A Metastasis and Chemoresistance Signature (MCS) scoring system was built and validated based on metastasis- and chemoresistance-related genes using gene expression data of PC, and the model was applied to single-cell RNA sequencing data. The influence of linker histone H1.2 (H1–2) on PC was explored through in vitro and in vivo experiments including proliferation, invasion, migration, drug sensitivity, rescue experiments and immunohistochemistry, emphasizing its regulation with c-MYC signaling pathway. A novel MCS scoring system accurately predicted PC patient survival and was linked to chemoresistance and epithelial-mesenchymal transition (EMT) in PC single-cell RNA sequencing data. H1–2 emerged as a significant prognostic factor, with its high expression indicating increased chemoresistance and EMT. This upregulation was mediated by c-MYC, which was also found to be highly expressed in PC tissues. The MCS scoring system offers insights into PC chemoresistance and metastasis potential. Targeting H1–2 could enhance therapeutic strategies and improve PC patient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. TMPRSS4 Promotes Cell Proliferation and Inhibits Apoptosis in Pancreatic Ductal Adenocarcinoma by Activating ERK1/2 Signaling Pathway.
- Author
-
Gu, Jianyou, Huang, Wenjie, Zhang, Junfeng, Wang, Xianxing, Tao, Tian, Yang, Ludi, Zheng, Yao, Liu, Songsong, Yang, Jiali, Zhu, Liwei, Wang, Huaizhi, and Fan, Yingfang
- Subjects
CELL proliferation ,PANCREATIC cancer ,ADENOCARCINOMA ,IMMUNOSTAINING ,APOPTOSIS ,CANCER cell growth ,PANCREATIC tumors - Abstract
Transmembrane protease serine 4 (TMPRSS4) is upregulated in various kinds of human cancers, including pancreatic cancer. However, its biological function in pancreatic ductal adenocarcinoma (PDAC) remains unclear. In the current study, real-time qPCR, immunohistochemical staining, Western blotting, and database (Cancer Genome Atlas and Gene Expression) analysis revealed remarkable overexpression of TMPRSS4 in PDAC tissue as compared to non-tumor tissue. The TMPRSS4 overexpression was associated with poor prognosis of PDAC patients. Moreover, multivariate analysis revealed that TMPRSS4 serves as an independent risk factor in PDAC. We performed gain-and loss-of-function analysis and found that TMPRSS4 promotes cellular proliferation and inhibits apoptosis of PDAC cells both in vitro and in vivo. Furthermore, we showed that TMPRSS4 might promote cell proliferation and inhibit apoptosis through activating ERK1/2 signaling pathway in pancreatic cancer cells. These findings were validated by using ERK1/2 phosphorylation inhibitor SCH772984 both in vitro and in vivo. Taken together, this study suggests that TMPRSS4 is a proto-oncogene, which promotes initiation and progression of PDAC by controlling cell proliferation and apoptosis. Our findings indicate that TMPRSS4 could be a promising prognostic biomarker and a therapeutic target for the treatment of pancreatic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Silencing ubiquitin‐conjugating enzyme 2C inhibits proliferation and epithelial–mesenchymal transition in pancreatic ductal adenocarcinoma.
- Author
-
Wang, Xianxing, Yin, Liangyu, Yang, Ludi, Zheng, Yao, Liu, Songsong, Yang, Jiali, Cui, Hongjuan, and Wang, Huaizhi
- Subjects
UBIQUITIN-conjugating enzymes ,CELL migration ,PROTEASOMES ,CELL cycle ,CELL proliferation ,PANCREATIC cancer - Abstract
Ubiquitin‐conjugating enzyme 2C (UBE2C) is a core ubiquitin‐conjugating enzyme in the ubiquitin–proteasome system that promotes cell cycle progression. Previous studies have indicated that UBE2C mediates tumorigenesis and progression in various cancers, but its role in pancreatic ductal adenocarcinoma (PDAC) remains unclear. This study elucidated the function of UBE2C in PDAC tumorigenesis and progression by determining UBE2C expression via real‐time qPCR, western blotting and immunohistochemistry. The associations between UBE2C expression and clinicopathological characteristics and survival were assessed using a tissue microarray based on a multicentre PDAC cohort. We found that UBE2C was strongly expressed in PDAC patient tissues and was negatively associated with clinical stage, lymph node metastasis, perineural invasion and survival (all P < 0.05). Multivariate analysis revealed that high UBE2C expression is an independent risk factor for PDAC (P = 0.001). In the PDAC cell lines CFPAC‐1 and Panc‐1, silencing UBE2C suppressed cell proliferation by inducing G1/S arrest mediated by downregulation of cyclin D1. Furthermore, UBE2C knockdown decreased the migration of PDAC cells in vitro by downregulating epithelial–mesenchymal transition (EMT). RNA‐seq analysis showed that upon silencing UBE2C in CFPAC‐1 cells, cyclin D1 and vimentin were downregulated by approximately 3.5‐fold and 2.6‐fold, respectively, and the major enriched pathways were related to cell cycle progression. Experiments on tumour‐bearing mice injected with CFPAC‐1 cells indicated that UBE2C depletion significantly inhibits tumour growth in vivo. These results suggest that UBE2C is involved in the development and progression of PDAC by regulating cell proliferation and EMT. UBE2C is a novel potential therapeutic target for pancreatic cancer. Database: Data are available in the GEO database under accession number GSE137172. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Prognostic Values of CD38+CD101+PD1+CD8+ T Cells in Pancreatic Cancer.
- Author
-
Zhang, Mengjie, Yang, Jiali, Zhou, Jian, Gao, Weiwu, Zhang, Yi, Lin, Yuxin, Wang, Huaizhi, Ruan, Zhihua, and Ni, Bing
- Subjects
- *
T cells , *PANCREATIC cancer , *CANCER cells , *THERAPEUTICS , *FLOW cytometry - Abstract
Programmed death-1 (PD-1), a key immune checkpoint molecule, has been developed as an oncotherapy target for various carcinomas. However, treatment with anti-PD-1 elicited only a minimal effect in pancreatic ductal adenocarcinoma (PDAC). Subsequent studies revealed the existence of a subset of PD-1+ T cells coexpressing CD38 and CD101, representing a fixed dysfunctional subpopulation that are not able to be rescued by anti-PD-1 immunotherapy. However, whether this subpopulation of PD-1 expressing CD8+ T cells could be useful in predicting PDAC stage or prognosing survival is unknown. In this study, we used flow cytometry and immunofluorescence assay to analyze the expression of CD38 and CD101 in 183 clinical PDAC samples, including 84 of peripheral blood and 99 of surgical tissues. High coexpression of CD38/CD101 on peripheral PD-1+CD8+ T cells or tumor-infiltrating lymphocytes (TILs) was found to be most significantly correlated with Tumor/Node/Metastasis (T/N/M) classification and clinical stage, in contrast PD-1+CD8+ T cells could not correlate with T classification. CD38/CD101 co-repression on TILs also correlated with the poor survival in these PDAC patient samples. Our data suggest that CD38/CD101 might represent a more helpful biomarker than PD-1 alone for diagnosis and prognosis of PDAC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
- Author
-
Li, Jian, Wang, Yunchao, Ge, Jiayun, Li, Wenhua, Yin, Liangyu, Zhao, Zhiping, Liu, Songsong, Qin, Huan, Yang, Jiali, Wang, Lijiang, Ni, Bing, Liu, Yongkang, and Wang, Huaizhi
- Subjects
MOUSE leukemia viruses ,METASTASIS ,PANCREATIC cancer ,CANCER prognosis ,CANCER invasiveness - Abstract
Background/Aims: Cancer stem cells (CSCs) are largely responsible for tumor relapse and metastatic behavior. Doublecortin-like kinase 1 (DCLK1) was recently reported to be a biomarker for gastrointestinal CSCs and involved in the epithelial-mesenchymal transition (EMT) and tumor progression. B cell-specific Moloney murine leukemia virus insertion site 1 (Bmi-1) is a crucial regulator of CSC self-renewal, malignant transformation and EMT, and a previous study from our group showed that Bmi-1 is upregulated in pancreatic cancer progression and participates in EMT. However, it remains unclear whether DCLK1 is involved in pancreatic cancer or whether DCLK1 is associated with the altered level of Bmi-1 expression. Methods: The correlation of DCLK1 expression and clinical features of pancreatic cancer was analyzed in 210 paraffin-embedded archived pancreatic cancer specimens by immunohistochemical analysis. The biological effects of DCLK1 siRNA on cells were investigated by examining cell proliferation using a cell counting kit and cell colony assays, cell migration by wound healing assay and cell invasion by Transwell invasion assay. We further investigated the effect of therapeutic siRNA targeting DCLK1 on pancreatic cancer cell growth in vivo. Moreover, the molecular mechanism by which DCLK1 upregulates Bmi-1 expression was explored using real-time PCR, western blotting and Co-immunoprecipitation assay. Results: DCLK1 is overexpressed in pancreatic cancer and is related to metastasis and prognosis. Knockdown of DCLK1 markedly suppressed cell growth in vitro and in vivo and also inhibited the migration and invasion of pancreatic cancer cells. Furthermore, we found that DCLK1 silencing could inhibit EMT in cancer cells via downregulation of Bmi-1 and the mesenchymal markers Snail and Vimentin and upregulation of the epithelial marker E-cadherin. Moreover, high DCLK1 expression in human pancreatic cancer samples was associated with a mesenchymal phenotype and increased cell proliferation. Further co-immunoprecipitation indicated that DCLK1 did not interact with Bmi-1 directly. Conclusion: Our data suggest that upregulation of DCLK1 may contribute to pancreatic cancer metastasis and poor prognosis by increasing Bmi-1 expression indirectly. The findings indicate that inhibiting DCLK1 expression might be a novel strategy for pancreatic cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Microarray expression profile analysis of circular RNAs in pancreatic cancer.
- Author
-
Guo, Shixiang, Xu, Xuejun, Ouyang, YongshENg, Wang, Yunchao, Yang, Jiali, Yin, Liangyu, Ge, Jiayun, and Wang, Huaizhi
- Subjects
MICROARRAY technology ,PANCREATIC cancer ,POLYMERASE chain reaction ,BIOLOGICAL tags ,CANCER treatment - Abstract
Pancreatic cancer remains one of the most malignant tumors with a poor prognosis. Despite advances in diagnosis and treatment, no reliable biomarkers are available for clinical practice. Circular RNAs (circRNAs) are a novel class of endogenous non‑coding RNA, which are abundant, stable and conserved, and serve crucial roles in disease, particularly in cancer. The purpose of the present study was to investigate the expression profile of circRNAs in 20 pancreatic cancer tissues and corresponding paracancerous tissues using arraystar human circRNA array analysis, high‑throughput circRNA microarray, bioinformatic analysis and reverse transcription‑quantitative polymerase chain reaction. It was revealed that the circRNAs expression profile was significantly different between pancreatic cancer tissue and paracancerous tissue, which indicates a potential role in pancreatic cancer. It was predicted that circRNAs may act as a micro RNA sponge to modulate gene expression in pancreatic cancer. Additionally, microarray expression analysis data was submitted to the Gene Expression Omnibus under accession no. GSE79634. The present study revealed that circRNAs expression was visibly diverse in pancreatic cancer compared with paracancerous tissue and provides more reliable biomarkers and new insights into the mechanisms of pancreatic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Integration of transcriptome and cistrome analysis identifies RUNX1-target genes involved in pancreatic cancer proliferation.
- Author
-
Liu, Songsong, Xie, Fuming, Gan, Lang, Peng, Tao, Xu, Xuejun, Guo, Shixiang, Fu, Wen, Wang, Yunchao, Ouyang, Yongsheng, Yang, Jiali, Wang, Xianxing, Zheng, Yao, Zhang, Junfeng, and Wang, Huaizhi
- Subjects
- *
PANCREATIC cancer , *RUNX proteins , *TUMOR growth , *RNA sequencing , *BIOMARKERS - Abstract
The extremely high proliferation rate of tumor cells contributes to pancreatic cancer (PC) progression. Runt-related transcription factor 1(RUNX1), a key factor in hematopoiesis that was correlated with tumor progression. However, the role of RUNX1 in PC proliferation was still unclear. We found that RUNX1 was significantly upregulated in PC tissues and its expression was negatively associated with prognosis of PC patients in a multicenter analysis according to immunohistochemical (IHC). RUNX1 downregulation in PC resulted in a significantly reduced cell proliferation rate, which was consistent with in vivo subcutaneous tumor formation assay results. RNA-seq and ChIP-seq results revealed that a portion of target genes, including HAP1 , GPRC5B , PTPN21 , VHL and EN2 , were regulated by RUNX1 , a finding successfully validated by ChIP-qPCR, qRT-PCR and Western blot. Subsequently, IHC and proliferation assays showed these target genes to be dysregulated in PC, affecting tumor growth. Our data suggest that RUNX1 plays an oncogenic role in tumor proliferation and is a potential prognostic biomarker and therapeutic target for PC. • RUNX1 was upregulated in PC and correlated with PC progression. • RUNX1 affected PC cell growth in vitro and in vivo. • RNA-seq and ChIP-seq analysis revealed the underlying targets by which RUNX1 affected PC proliferation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.